RT Book, Section
A1 Oppelt, Thomas F.
A2 Sutton, S. Scott
SR Print(0)
ID 7254238
T1 Chapter 46. Osteoporosis
T2 McGraw-Hill's NAPLEX® Review Guide
YR 2011
FD 2011
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-175562-7
LK accesspharmacy.mhmedical.com/content.aspx?aid=7254238
RD 2024/04/19
AB Osteoporosis  is  a  disease  of  the  skeleton  marked  by  low  bone  mass  and  microarchitectural  degeneration  of  bone  tissue,  with  a  subsequent  increase  in  fracture  risk.1,2  In  the  United  States,  10  million  people  are  estimated  to  have  osteoporosis  and  almost  34  million  more  are  believed  to  have  osteopenia  (low  bone  mass),  placing  them  at  risk  of  developing  osteoporosis.3  Studies  suggest  that  over  2  million  osteoporosis-related  fractures  occur  in  the  United  States  annually,  with  an  estimated  cost  of  $17  billion.4,5  Some  speculate  that  the  prevalence  of  these  bone  metabolism  disorders  may  be  on  the  rise,  in  part,  due  to  a  decrease  in  the  overall  routine  utilization  of  hormone  replacement  therapy  (HRT)  for  most  postmenopausal  women.  In  2002,  the  Women's  Health  Initiative  (WHI)  was  published  suggesting  that  the  risks  of  long-term  estrogen  plus  progestin  supplementation  outweighed  any  benefits  (namely,  the  FDA-approved  prevention  of  osteoporosis).5  Also,  while  osteoporosis  is  less  prevalent  in  men  than  women,  men  account  for  almost  30%  of  low  bone  mass  related  (fragility)  fractures.4